Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 99.86% is 41% above its 5-year average of 70.88%, near the high end of its 5-year range (0.00%–100.00%).
0.00% above its 12-month average of 99.86%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
99.86%
GROSS MARGIN AVG TTM
99.86%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
70.88%
GROSS MARGIN AVG 10Y
73.71%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
-0.14%
CURRENT VS 5Y AVG
+40.89%
CURRENT VS 10Y AVG
+35.47%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+141.32%
vs the sector median at left
Protagonist Therapeutics, Inc.
Market Cap
$8.92B
Gross Margin
99.86%
TTM Avg
99.86%
3Y Avg
100.00%
5Y Avg
70.88%
Market Cap
$8.93B
Gross Margin
46.69%
TTM Avg
47.45%
3Y Avg
49.39%
5Y Avg
49.15%
Market Cap
$8.97B
Gross Margin
93.24%
TTM Avg
91.97%
3Y Avg
90.98%
5Y Avg
60.65%
Market Cap
$8.72B
Gross Margin
101.98%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$8.67B
Gross Margin
100.00%
TTM Avg
-161.83%
3Y Avg
-33.28%
5Y Avg
-5.52%
Market Cap
$9.21B
Gross Margin
46.69%
TTM Avg
47.45%
3Y Avg
49.39%
5Y Avg
49.15%
Market Cap
$8.38B
Gross Margin
14.38%
TTM Avg
17.24%
3Y Avg
38.82%
5Y Avg
59.22%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) | $8.92B | 99.86% | 99.86% | 100.00% | 70.88% |
| Bruker Corporation (BRKRP)vs › | $8.93B | 46.69% | 47.45% | 49.39% | 49.15% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | 93.24% | 91.97% | 90.98% | 60.65% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.72B | 101.98% | 100.00% | 100.00% | 100.00% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | 100.00% | -161.83% | -33.28% | -5.52% |
| Bruker Corporation (BRKR)vs › | $9.21B | 46.69% | 47.45% | 49.39% | 49.15% |
| Insulet Corp. (PODD)vs › | $9.33B | 71.08% | 70.71% | 67.87% | 67.39% |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 14.38% | 17.24% | 38.82% | 59.22% |
| Vaxcyte, Inc. (PCVX)vs › | $9.63B | 0.00% | 0.00% | 0.00% | 0.00% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 93.34% | 92.85% | 69.90% | 46.60% |
Gross Margin
99.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 99.28% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 1.86% |
| 2022-03-31 | 96.76% |
| 2021-12-31 | 90.50% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 133.87% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
